Detailed narrative
Stars Performance and Strategy
Humana remains confident in achieving top quartile Stars results for Bonus Year '28, defining this as Stars revenue PMPM 10% above the peer group median. The company demonstrated significant operational progress, with the rate of improvement for 11 out of 12 de-identified HEDIS and patient safety metrics outpacing historical CAGRs.
For BY '29, member engagement efforts have maintained momentum, with a 5% lead in quality improvement rate on a per-member basis in key HEDIS metrics at the end of Q2. New members are performing in line with or better than renewing members in terms of engagement.
Operating Model Transformation
The company is actively transforming its operating model to be simpler, leaner, and faster, focusing on efficiency, innovation, and talent. Initiatives include centralizing operations like utilization management (11 markets into 1 team), expanding outsourcing in finance and HR, and optimizing vendor relationships in IT.
These efforts have already yielded hundreds of millions of dollars in value in 2026, with further progress expected through continued simplification of infrastructure and processes.
2027 MA Bid Approach
Humana's primary goal for 2027 MA bids is to make necessary margin progression to stay on track for its 2028 sustainable 3% pretax margin commitment. This will be driven by clinical excellence, operating efficiency, benefit adjustments, and targeted plan exits.
Approximately 600,000 members are expected to be impacted by plan exits, primarily in lower-performing plans, with a goal to recapture a significant portion of this volume, similar to the 40% recapture rate in 2025. The strategy prioritizes retaining members in higher-value plans, particularly those with greater value-based care penetration.
Cost Trend Observations
The company's 2026 cost trend assumption of high single-digits (7-8%) for medical and pharmacy remains in line with expectations. There has been slight favorability in the inpatient space, driven by both lower admits per 1,000 and lower unit costs. This favorability is more pronounced among members engaged with value-based providers, which management views as further evidence of stabilization in the MA trend environment.
Drug trend is expected to tick modestly higher in 2027 due to the health technology pipeline.
Capital Allocation and Balance Sheet Efficiency
Humana continues to enhance its balance sheet efficiency, including the establishment of $1.5 billion in contingent capital facilities using pre-capitalized trust securities (PCAPs), a first in the healthcare space. This provides low-cost, long-term liquidity without immediate balance sheet impact. The company also announced an agreement to divest its minority interest in Gentiva for approximately $900 million, which will largely fund the recent acquisition of MaxHealth.
These actions reflect a prudent capital deployment approach focused on strengthening the balance sheet.
Medicaid Expansion and Board Appointments
Humana is expanding its Medicaid platform, having been awarded a statewide Illinois Medicaid managed care contract set to go live in January 2027. This marks Humana as the only new entrant among five incumbents. Additionally, Paul Smith (Chief Commercial Officer at Anthropic) and Fred Crawford (former President and COO at Aflac) have been appointed to Humana's Board of Directors, bringing expertise in technology transitions, finance, and operations to support the company's journey as a consumer healthcare company.